CLIANTHA RESEARCH LIMITED
Opposite Pushparaj Towers, Near Judges Bungalows, Bodakdev, Ahmedabad-380 054.

Ophthalmology Research Papers

Reproxalap Improves Signs and Symptoms of Allergic Conjunctivitis in an Allergen Chamber: A Real-World Model of Allergen Exposure

A Phase 2 Exploratory Study of a Novel Interleukin-1 Receptor Inhibitor (EBI-005) in the Treatment of Moderate-to-Severe Allergic Conjunctivitis.

Fel d 1-derived synthetic peptide immuno-regulatory epitopes show a long-term treatment effectin cat allergic subjects.

Randomized, double-blind, placebo-controlled trial of standardized ragweed sublingual-liquidimmunotherapy for allergic rhinoconjunctivitis.

Goldstein MH, Tubridy KL, Agahigian J, Furfine E, Magill M, Kovalchin J, Golden K, Zarbis- Papastoitsis G, Soong F, Salapatek AM, Sternberg G. A phase 2 exploratory study of a novel interleukin-1 receptor inhibitor (EBI-005) in the treatment of moderate-to-severe allergic conjunctivitis. Eye & Contact Lens 2015; 41(3):145-55.

Williams J, Gow J, Klier S, McCue S, Salapatek A, McNamara T. Non-clinical pharmacology, pharmacokinetics, and safety findings for the antihistamine bepotastine besilate. Curr Med Res Opin 2010; 26:2329-2338.

Krueger JG, Ochs HD, Patel P, Gilkerson E, Guttman-Yassky E, Dummer W. Effect of Therapeutic Integrin (CD11a) Blockade with Efalizumab on Immune Responses to Model Antigens in Humans: Results of a Randomized, Single Blind Study. J Invest Dermatol 2008; 128:2615-2624.

Monroe E, Finn A, Patel P, Guerrero R, Ratner P, Bernstein D. Efficacy and safety of desloratadine 5 mg once daily in the treatment of chronic idiopathic urticaria: A double-blind, randomized, placebo-controlled trial. J Am Acad Dermatol 2003; 48:535-541

Papp K, Bissonnette R, Krueger J, Carey W, Gratton D, Gulliver W, Lui H, Lynde C, Magee A, Patel P, et al. The treatment of moderate to severe psoriasis with a new anti-CD11a monocolonal antibody. J Am Acad Dermatol 2001; 45:665-674

Patel P, Danzig M. Comparative efficacy and safety of Loratadine and Cetirizine in patients with chronic idiopathic urticaria. Adv Ther 1997; 14:318-322.

Sadoway T, Nelson V, Zizek W, Tenorio N, Patel P, Lee F, Salapatek AM. Allergic phenotyping and prevalence of skin prick test positive subjects in New Jersey, USA consistent with a more northern clinical site located in the Greater Toronto Area (GTA), Canada. Allergy 2016; 71(S102): 484-485.

Lorentz H, Recker S, Soong F, Salapatek AM. Retrospective Analysis of Ocular Allergic Conjunctivitis (AC) Responders (RS) and Non-Responders (NRS) during Screening in an Environmental Exposure Chamber (EEC). J Allergy Clin Immunol 2016; 137(2):AB164.

Goldstein MH, Tubridy K, Agahigian J, Magill M, Kovalchin J, Salapatek AM, Furfine ES, Celniker Comparison of Two Clinical Repeat Allergen Challenge Models to Evaluate EBI-005 in the Late Phase Inflammatory Response in Allergic Conjunctivitis. Invest Ophthalmol Vis Sci 2015; 56(7):5872.

Lorentz H, Recker S, Shi C, Mun J, Salapatek AM, Soong F. A low and high humidity controlled environmental exposure (EEC) model: a highly specific and sensitive model to measure in vivo CL dehydration. Invest Ophthalmol Vis Sci 2015; 56(7):6108.

Soong F, Lorentz H, Recker S, Shi C, Mun J, Salapatek AM. Ocular signs and symptoms in non- symptomatic CL wearers under controlled humidity settlings in an environmental exposure chamber (EEC). Invest Ophthalmol Vis Sci 2015; 56(7):6114.

Soong F, Lorentz H, Subbaraman L, Jones LW, Salapatek AM. The controlled low humidity environmental exposure chamber (LH-EEC) is a sensitive and specific tool for study of the signs and symptoms of dry eye (DE) versus non-dry eye (NDE) participant. Invest Ophthalmol Vis Sci 2014; 55(13):2011.

Salapatek AM, Lorentz H, Soong F. A novel validated electronic data acquisition tablet (ePDAT) facilitates and standardizes patient reported outcomes (PRO) in patients with dry eye syndrome (DE) studied in environmental exposure chamber (EEC) and fields trials. Invest Ophthalmol Vis Sci 2014; 55(13):2011.

Subbaraman L, McCanna D, Lorentz H, Soong F, Salapatek AM, Jones L. Tear Cytokines in Non- Dry Eye and Dry Eye Participants After Exposure to a Low Humidity Environmental Exposure Chamber. Invest Ophthalmol Vis Sci 2014; 55(13):3682.

Patel P, Soong F, Varikooty J, Keir N, Jones L. Ocular Signs and Symptoms in Contact Lens Wearers in a Controlled Low Humidity Environmental Exposure Chamber (LH-EEC), A Natural Provocation Research Model. Invest Ophthalmol Vis Sci 2013; 54:5473.

Soong F, Varikooty J, Kier N, Jones L, Patel P. In-vivo wettablity of contact lenses worn in a low humidity environmental exposure chamber (LH-EEC) show comparable changes to traditional field trials. Invest Ophthalmol Vis Sci 2013; 54:499.

Jones LW, Varikooty JP, Keir NJ, Soong F, Patel P. The Evaluation of Lid Wiper Epitheliopathy in Contact Lens Wearers in a Controlled Low Humidity Environmental Exposure Chamber. Invest Ophthalmol Vis Sci 2013; 54:5475.

Soong F, Salapatek A, Landers A. Differences Between Contact Lenses and Spectacle Wear Based on Mean Blink Rate and Relative Ocular Comfort Evaluated and Discerned in a Low Humidity Dry Eye Chamber (DEC) Model. Invest Ophthalmol Vis Sci 2012; 53:4712.

Tort M, Lay B, Danno R, Ornberg R, Williams G, Soong F, Salapatek AM. Imaging System for Ocular Surface: Objective Assessment of Conjunctival Hyperemia. ISS France 2012.

Tort M, Lay B, Danno R, Ornberg R, Williams G, Wheeler J, Lange D, Narvekar A, Salapatek AM, Soong F, Lee J, Wilson D. Development of an imaging system for the objective assessment of conjunctival hyperemia. ARVO 2011.

Soong F, Lee J, Salapatek A, Landers A. Contact Lenses and Spectacles Compared in a Low Humidity Environment Chamber (LHE): Discernable Differences in Tear Osmolarity, Symptoms, and Comfort. American Academy of Optometry Annual Conference 2011.

Soong F, Lee J, Landers A, Salapatek A. Evaluation of a Novel Algorithm and Low Humidity Environment Chamber (LHE) to Classify Subjects as Contact Lens-Induced Dry Eye (CLIDE) or Non-CLIDE. American Academy of Optometry Annual Conference 2011.

Salapatek A, Wilson D, Patel D, D'Angelo P, Liu J, Bernstein J, et al. Specific Ocular Symptoms are Evoked in NARC Patients, Following Exposure to Simulated Weather Change and Environmental Irritant Triggers in an Environmental Exposure Chamber. Invest Ophthalmol Vis Sci 2011; 52(14):6423.

Salapatek AM, Liu J, Patel D, D'Angelo P, Lee J. A Natural Aerosolized Allergen Environmental Exposure Chamber (EEC) Model for the Study of Allergic Conjunctivitis Evokes Significant and Reproducible Ocular Symptoms in Patients With Seasonal Allergic Rhinoconjunctivitis: Comparison of Two Studies Conducted Over Two Years, Out of Ragweed Season. Invest Ophthalmol Vis Sci 2010; 51(13):1926.

Lee J, Wilson D, Patel D, D'Angelo P, Liu J, Song Y, Bernstein J, Tsitoura D, Murdoch R, Salapatek AM. The Non-Allergic RhinoConjunctivitis (NARC) Environmental Exposure Chamber (EEC) Model Induces Significant Ocular Symptoms Specifically in NARC Patients. Ann Allergy Asthma Immunol 2010; 105:A13.

Soong F, Patel P, Lee JSY, Wilson D, and Salapatek A. Evaluation of the Efficacy of Dexamethasone to Improve the Signs and Symptoms of Dry Eye Syndrome (DES) in a Low Humidity Environment (LHE) Chamber Model. Invest Ophthalmol Vis Sci 2009; 50:4657.

Soong F, Patel P, Lee J.S.Y, Wilson D, Salapatek AM: Evaluation of the Efficacy of Dexamethasone to Improve the Signs and Symptoms of Dry Eye Syndrome (DES) in a Low Humidity Environment (LHE) Chamber Model. Invest Ophthalmol Vis Sci 2009.

Salapatek AM, Soong F, Wilson D, Pozza L, Patel P: Validation of a Clinical Model to Study Dry Eye Syndrome (DES) in a Controlled Low Humidity Environment (LHE) Chamber. Invest Ophthalmol Vis Sci 2009.

Pozza L, Salapatek AM, Soong F, Wilson D, Patel D, Patel P: Nasal spray antihistamine (Livostin®) prophylactic treatment improves ocular redness symptoms in a Conjunctival Allergen Challenge model. Ann Allergy Asthma Immunol 2009; 102:A119.

Salapatek A, Pozza L, Patel D, Patel P. Levocetirizine, but Not Montelukast, Is Effective in Alleviating Ocular Symptoms in Allergic Patients Exposed to Ragweed Pollen in an Environmental Exposure Chamber (EEC) Model. Invest Ophthalmol Vis Sci 2008; 49:416.

Salapatek AM, Pozza L, Patel D, Patel P: Levocetirizine, but Not Montelukast, Is Effective in Alleviating Ocular Symptoms in Allergic Patients Exposed to Ragweed Pollen in an Environmental Exposure Chamber (EEC) Model. Invest Ophthalmol Vis Sci 2008; 49:416.

Pozza L, Salapatek AM, Patel D, Pipkin J, Zimmerer R, Patel P: Ocular Symptoms Are Significantly Improved by Budesonide Nasal Solution (Captisol-Enabled®) Compared to Micronized Suspension (Rhinocort Aqua®) or Placebo in Patients With Seasonal Allergic Conjunctivitis (SAC) Studied in an Environmental Exposure Chamber (EEC) Model. Invest Ophthalmol Vis Sci 2008; 49:423.

Patel P, Wheeler W, Sacks H. Azelastine Nasal Spray Improves Nasal Symptoms of Seasonal Allergic Rhinitis in 15 Minutes in an Environmental Exposure Chamber. Annals of Allergy, Asthma and Immunology 2008; 100:A85.

Pozza LM, Salapatek A, Patel D, Pipkin J, Zimmerer R, Patel P. Ocular Symptoms Are Significantly Improved by Budesonide Nasal Solution (Captisol-Enabled(R)) Compared to Micronized Suspension (Rhinocort Aqua(R)) or Placebo in Patients With Seasonal Allergic Conjunctivitis (SAC) Studied in an Environmental Exposure Chamber (EEC) Model. Invest Ophthalmol Vis Sci 2008; 49:423.

McCue S, Barney B, Patel P, Salapatek AM. Development of low humidity environment (LHE) facility for the clinical study of dry eye syndrome. Tear Film and Ocular Surface Society 2007.